As Arrowhead prepares to unveil key data in alpha-1 antitrypsin deficiency, its life is made easier by Vertex’s second failure in the disease.
But this week two transactions did squeak through.
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
Biogen needs blood tests for amyloid beta to progress quickly – and several are in the pipeline.
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
A green light from the US regulator for aducanumab is a huge boost for Biogen, but not everyone will be celebrating.